{"id":6135,"date":"2024-09-03T10:58:03","date_gmt":"2024-09-03T10:58:03","guid":{"rendered":"https:\/\/demopublication.edutechy.xyz\/?p=6135"},"modified":"2025-04-26T09:53:21","modified_gmt":"2025-04-26T09:53:21","slug":"chapter-18-drug-safety-evaluation-in-special-population","status":"publish","type":"post","link":"https:\/\/sproutpublication.com\/index.php\/2024\/09\/03\/chapter-18-drug-safety-evaluation-in-special-population\/","title":{"rendered":"Chapter 18: Drug Safety Evaluation in Special Population"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-right:20px;--awb-padding-left:20px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-border-color:var(--awb-color3);--awb-border-style:solid;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\" style=\"--awb-content-alignment:justify;--awb-font-size:16px;\"><p><strong>Author: <\/strong>Mrs. Saba Ruksaar<br \/>\n<strong>Volume: <\/strong>01<br \/>\n<strong>First Online: <\/strong>31 August 2024<br \/>\n<strong>Pages: <\/strong> 272-289<br \/>\n<strong>DOI:<\/p>\n<\/div><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-text fusion-title-size-two\" style=\"--awb-text-color:var(--awb-color8);--awb-font-size:20px;\"><h2 class=\"fusion-title-heading title-heading-left\" style=\"font-family:&quot;Roboto&quot;;font-style:normal;font-weight:700;margin:0;font-size:1em;\">Abstract<\/h2><\/div><div class=\"fusion-separator\" style=\"align-self: flex-start;margin-right:auto;margin-bottom:20px;width:100%;max-width:8%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"--awb-height:20px;--awb-amount:20px;--awb-sep-color:var(--awb-custom_color_1);border-color:var(--awb-custom_color_1);border-top-width:3px;\"><\/div><\/div><div class=\"fusion-text fusion-text-2\" style=\"--awb-content-alignment:justify;--awb-font-size:16px;--awb-text-font-family:&quot;Roboto&quot;;--awb-text-font-style:normal;--awb-text-font-weight:400;\"><p>Drug safety evaluation in special populations is a critical aspect of clinical pharmacology, ensuring that medications are safe and effective across diverse groups. Special populations include pregnant women, children, the elderly, and individuals with comorbidities or genetic variations. These groups often have unique physiological characteristics that can alter drug pharmacokinetics and pharmacodynamics, increasing the risk of adverse drug reactions (ADRs) or therapeutic failure. Evaluating drug safety in these populations involves tailored clinical trials, dose adjustments, and careful monitoring to account for altered metabolism, organ function, and drug interactions. Regulatory guidelines often require specific studies to assess drug effects in these populations, as their responses may differ significantly from the general population. This approach ensures that drug therapy is optimized, reducing the risk of harm and improving treatment outcomes in vulnerable groups.<\/p>\n<p><strong>Keywords:<\/strong> Drug Safety Evaluation, Special Populations, Clinical Pharmacology, Pregnant Women, Children, Elderly, Comorbidities<\/p>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[144],"tags":[],"class_list":["post-6135","post","type-post","status-publish","format-standard","hentry","category-pharmacovigilance"],"_links":{"self":[{"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/posts\/6135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/comments?post=6135"}],"version-history":[{"count":4,"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/posts\/6135\/revisions"}],"predecessor-version":[{"id":7330,"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/posts\/6135\/revisions\/7330"}],"wp:attachment":[{"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/media?parent=6135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/categories?post=6135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/tags?post=6135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}